The mammoth task of vaccinating India’s billion+ population: List of COVID vaccines to be available in 2021
New Delhi: India has a mammoth task to vaccinate its billion-plus population against the deadly COVID-19 disease which has led to huge loss of lives, crippling economy and a crumbling health infrastructure. To accomplish the daunting task, the Centre has so far given nod to eight coronavirus vaccines that would be available in the coming months.The government has issued emergency use authorisation to Serum Institute of India for Novavax, Bharat Biotech’s nasal vaccine, Biological E, Zydus Cadila, Gennova and Sputnik V. Notably, SII’s Covishield and Bharat Biotech’s Covaxin are already in use since January, while Russia’s Sputnik V doses are expected to be administered from next week.Covaxin: Bharat Biotech’s Covaxin was given the nod by the Drugs Controller General of India (DCGI) in January. Notably, the drug regulator has accorded permission to conduct the Phase II/III clinical trial of Covaxin in the age group 2 to 18 years. Bharat Biotech has assured that it would provide 3.32 crore doses in July, and expand it to 7.82 crores in August.Covishield: The Oxford-AstraZeneca vaccine which is being manufactured by SII in Pune has also been use since January. SII has assured of producing 10 crore doses of Covishield by August.Intranasal: Bharat Biotech has asked to provide 10 crore doses of its intranasal vaccine ‘BBV154’. It is a novel adenovirus vectored, intranasal vaccine for COVID-19. The intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.Sputnik V: The Russian vaccine which is being marketed by Dr. Reddy's Laboratories in India has assured of 15.6 crore doses this year. The Sputnik V vaccine is expected to be administered next week.Zydus Cadila: The Ahmedabad-based pharmaceutical company has been authorised to provide its ZyCoV-D COVID vaccine. The company is expected to provide 5 crore doses by year-end.Novavax: The American pharmaceutical company in partnership with Serum Institute of India will be supplying covid-19 vaccine NVX-CoV2373 named Covovax this year. It has assured of providing 20 crore doses of Novavax by year-end.Gennova: The Centre has given the green signal to the Pune-based Gennova Biopharmaceuticals to provide vaccine doses against COVID. Gennova will be providing 6 crore doses.Biological E: Biological E Limited (BE) has received emergency authorisation for its protein subunit BECOV2A vaccine. Biological E is expected to produce 30 crore doses and the vaccine delivery is expected in August.The cumulative number of COVID-19 vaccine doses administered in the country stands at 17,91,77,029 as per the 8 pm provisional report released on May 13.